Last reviewed · How we verify
norepinephrine versus midodrine & octreotide
Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications.
Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications. Used for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.
At a glance
| Generic name | norepinephrine versus midodrine & octreotide |
|---|---|
| Sponsor | National Hepatology & Tropical Medicine Research Institute |
| Drug class | Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog |
| Target | Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Norepinephrine is a catecholamine that stimulates alpha and beta-adrenergic receptors to increase systemic vascular resistance and blood pressure. Midodrine is an alpha-1 adrenergic agonist that increases peripheral vasoconstriction, while octreotide is a somatostatin analog that reduces splanchnic blood flow and portal pressure. This combination is used in acute variceal hemorrhage management to maintain hemodynamic stability and reduce rebleeding risk.
Approved indications
- Acute variceal hemorrhage in portal hypertension
- Prevention of variceal rebleeding in cirrhotic patients
Common side effects
- Hypertension
- Tachycardia
- Headache
- Abdominal pain
- Hyperglycemia
- Peripheral ischemia
Key clinical trials
- Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. (PHASE4)
- Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: